Actively Recruiting Clinical Trials Focused on Pancreatic Cancer

Get Permission

THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on pancreatic cancer. These studies are investigating radiotherapy; cancer vaccines; combination treatments; novel cell therapies; response prediction; and more. All of the studies are listed on the National Institutes of Health website at 


Study Title: A Dose-Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer 

Study Type: Interventional/single-group assignment 

Study Sponsor and Collaborators: University of Colorado, Denver 

Purpose: To evaluate the safety of SBRT delivered in three fractions for patients with locally advanced pancreatic cancer who have received induction chemotherapy (FOLFIRINOX [leucovorin, fluorouracil, irinotecan, oxaliplatin] or gemcitabine and nab-paclitaxel [Abraxane]) 

Primary Outcome Measures: The maximum tolerated dose of SBRT in patients with locally advanced pancreatic cancer who have not developed distant disease progression after induction chemotherapies per standard of care [time frame: up to 3 months] 

Principal Investigator: Karyn C. Goodman, MD, University of Colorado, Denver; contact Robyn Swing, (720) 848-0607, robyn. Identifier: NCT02873598 


Study Title: A Randomized Study of a GM-CSF–Secreting Allogeneic Pancreatic Cancer Vaccine With or Without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas 

Study Type: Interventional/randomized/parallel assignment 

Study Sponsor and Collaborators: Sidney Kimmel Comprehensive Cancer Center 

Purpose: To study whether cyclophosphamide plus an immune system–activating pancreatic cancer vaccine (known as GVAX) with nivolumab [Opdivo] is more effective than cyclophosphamide/GVAX alone in altering the pancreatic tumor microenvironment (interleukin 17 expression) to aid in antitumor response 

Primary Outcome Measures: Median IL-17A expression in vaccine-induced lymphoid aggregates found in surgically resected pancreatic tumors [time frame: 4 years] 

Principal Investigator: Lei Zheng, MD, PhD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; contact Carol Judkins, RN, (410) 614-5241, Identifier: NCT02451982 


Study Title: Tumor-Associated Antigen (TAA)-Specific Cytotoxic T Lymphocytes Administered in Patients With Pancreatic Cancer 

Study Type: Interventional/nonrandomized/parallel assignment 

Study Sponsor and Collaborators: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital System; Pancreatic Cancer Action Network; The V Foundation for Cancer Research; Harris County Hospital District 

Purpose: To study the activity of five kinds of immune system cells called TAA-specific cytotoxic T lymphocytes (NY-ESO-1, MAGEA4, PRAME, survivin, and SSX2) in pancreatic cancer 

Primary Outcome Measures: Number of patients with treatment-related serious adverse events [time frame: 7 months], number of patients who received six infusions of multiTAA-specific T cells [time frame: 6 months] 

Principal Investigators: Yvonne Sada, MD; Anne Leen, PhD; Brandon Smaglo, MD; Baylor College of Medicine. Contact Dr. Smaglo, (713) 798-3342, Identifier: NCT03192462 


Study Title: BrUOG 292: FOLFOX-A for Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial 

Study Type: Interventional/single-group assignment 

Study Sponsor and Collaborators: Brown University, Lifespan, SouthCoast Medical Group, Memorial Hospital 

Purpose: To study the activity and side effects of FOLFOX-A (fluorouracil, oxaliplatin, leucovorin, and protein-bound paclitaxel) vs FOLFIRINOX in metastatic pancreatic cancer 

Primary Outcome Measures: Survival for patients with metastatic pancreatic cancer with first-line treatment with FOLFOX-A as compared with historical controls of gemcitabine alone [time frame: every 3 months for up to 5 years] 

Principal Investigator: Howard Safran, MD, Lifespan; (401) 863-3000 Identifier: NCT02080221 


Study Title: Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response 

Study Type: Observational/cohort 

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center 

Purpose: To develop a test to predict response of pancreatic cancer to different chemotherapy regimens 

Primary Outcome Measures: Progression-free survival [time frame: 36 months] 

Principal Investigator: Kenneth Yu, MD, Memorial Sloan Kettering Cancer Center; (646) 888-4188, Identifier: NCT03033927 


Study Title: Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer 

Study Type: Interventional/single-group assignment 

Study Sponsor and Collaborators: Medical College of Wisconsin 

Purpose: To study the efficacy of doxycycline, an oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic cancer following 8 weeks of treatment 

Primary Outcome Measures: Efficacy of doxycycline in inducing metakaryotic cell death in primary pancreatic tumors as measured by pathologic response [time frame: 3 months] 

Principal Investigator: Susan Tsai, MD, MHS, Medical College of Wisconsin; contact Medical College of Wisconsin Cancer Center, (414) 805-8900, Identifier: NCT02775695 

Editor’s Note: The clinical trials presented here do not represent all the trials listed on For the complete list, go to ■